|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash and cash equivalents | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Total cash and cash equivalents | |||||||||
| Accounts receivable | |||||||||
| Investments | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Total investments | |||||||||
| Separate account assets | |||||||||
| Separate account collateral held under securities lending agreements | |||||||||
| Property and equipment (net of accumulated depreciation and amortization of $1,929 and $1,692 at September 30, 2026 and December 31,2025, respectively) | |||||||||
| Intangible assets (net of accumulated amortization of $2,235 and $1,482 at September 30,2026 and December 31,2025, respectively | |||||||||
| Goodwill | |||||||||
| Operating lease right-of-use assets | |||||||||
| Other assets | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Total other assets | |||||||||
| Total assets | |||||||||
| Liabilities | |||||||||
| Accrued compensation and benefits | |||||||||
| Accounts payable and accrued liabilities | |||||||||
| Borrowings | |||||||||
| Separate account liabilities | |||||||||
| Separate account collateral liabilities under securities lending agreements | |||||||||
| Contingent consideration liabilities | |||||||||
| Deferred income tax liabilities | |||||||||
| Operating lease liabilities | |||||||||
| Other liabilities | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Total other liabilities | |||||||||
| Total liabilities | |||||||||
| Redeemable noncontrolling interests | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Subco | |||||||||
| Total redeemable noncontrolling interests | |||||||||
| Permanent equity | |||||||||
| Common stock, $0.01 par value;Shares authorized: 500,000,000 at September 30, 2026 and December 31, 2025; Shares issued: 156,276,289 at both September 30, 2026 and December 31, 2025, Shares outstanding:154,606,029 and 155,069,171 at September 30, 2026 and December 31, 2025, respectively | |||||||||
| Additional paid-in capital | |||||||||
| Retained earnings | |||||||||
| Accumulated other comprehensive loss | |||||||||
| Treasury stock, common, at cost (1,670,260 and 1,207,118 shares held at September 30, 2026 and December 31, 2025, respectively) | |||||||||
| Total BlackRock, Inc. stockholders’ equity | |||||||||
| Nonredeemable NCI - CIPs | |||||||||
| Consolidated Sponsored Investment Products | |||||||||
| Nonredeemable NCI - CIPs | |||||||||
| Nonredeemable NCI - Subco | |||||||||
| Total nonredeemable NCI - CIPs | |||||||||
| Total permanent equity | |||||||||
| Total liabilities, temporary equity and permanent equity |
Loading...